Pacritinib for Patients With Lower-Risk Myelodysplastic Syndromes (MDS)

计划入组 3 人 · 首次发布于 2015 年 6 月 11 日

The Tapering Dose of Luspatercept in Patients With Lower-risk Myelodysplastic Syndromes

计划入组 36 人 · 首次发布于 2023 年 6 月 29 日

Phase 1 Trial of ASTX727 in Subjects With Lower-risk Myelodysplastic Syndromes

计划入组 30 人 · 首次发布于 2019 年 4 月 8 日

Myelodysplastic syndrome(Calibr-Skaggs)

small molecule therapeutic (myelodysplastic syndrome)

blood cell differentiation stimulator (myelodysplastic syndrome)

The Lower Valley Hospital Association

United States

ADVANTAGE RISK MANAGEMENT CO., LTD.

Japan

TWG HEALTH RISK MANAGEMENT (PTY) LTD

South Africa

ESA Treatment Shows Survival Benefit in Lower-Risk Myelodysplastic Syndromes

Canakinumab Shows Promise in Treating Relapsed/Refractory Lower-Risk Myelodysplastic Syndromes

Halia Therapeutics Initiates Phase 2a Trial of First-in-Class NLRP3 Inhibitor HT-6184 for Lower-Risk Myelodysplastic Syndromes